Drug intelligence / Profile preview

Cytoplex-LZ

Development stage: Unknown
Lead developer: Anglo-French Drugs & Industries
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
Administration: Oral

Overview

Cytoplex-LZ is an oral probiotic and micronutrient combination capsule developed by Anglo-French Drugs & Industries. It is formulated with Lactobacillus spores (200 million spores), Vitamin B-complex, and elemental zinc (22.5 mg). Cytoplex-LZ is indicated to restore gut and vaginal microbial flora, reduce the severity of irritable bowel syndrome (IBS) symptoms, replenish B-vitamins lost during illness, and boost immunity to help control diarrhea, particularly viral diarrhea or diarrhea associated with antibiotic use.

Brand names: Cytoplex-LZ
Other names: Cytoplex-LZ CapsulesCytoplex-Lz

Beyond the preview

Go deeper on Cytoplex-LZ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytoplex-LZ.